These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 28339794

  • 1. Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial.
    Essebag V, Proietti R, Birnie DH, Wang J, Douketis J, Coutu B, Parkash R, Lip GYH, Hohnloser SH, Moriarty A, Oldgren J, Connolly SJ, Ezekowitz M, Healey JS.
    Europace; 2017 Oct 01; 19(10):1630-1636. PubMed ID: 28339794
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin.
    Jennings JM, Robichaux R, McElderry HT, Plumb VJ, Gunter A, Doppalapudi H, Osorio J, Yamada T, Kay GN.
    J Cardiovasc Electrophysiol; 2013 Oct 01; 24(10):1125-9. PubMed ID: 23889767
    [Abstract] [Full Text] [Related]

  • 3. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial.
    Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, Noack H, Oldgren J, Reilly P, Spyropoulos AC, Wallentin L, Connolly SJ.
    Thromb Haemost; 2015 Mar 01; 113(3):625-32. PubMed ID: 25472710
    [Abstract] [Full Text] [Related]

  • 4. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation.
    Black-Maier E, Kim S, Steinberg BA, Fonarow GC, Freeman JV, Kowey PR, Ansell J, Gersh BJ, Mahaffey KW, Naccarelli G, Hylek EM, Go AS, Peterson ED, Piccini JP, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators.
    Clin Cardiol; 2017 Sep 01; 40(9):746-751. PubMed ID: 28543401
    [Abstract] [Full Text] [Related]

  • 5. Interrupted versus uninterrupted novel oral anticoagulant peri-implantation of cardiac device: A single-center randomized prospective pilot trial.
    Ricciardi D, Creta A, Colaiori I, Scordino D, Ragni L, Picarelli F, Calabrese V, Providência R, Ioannou A, Di Sciascio G.
    Pacing Clin Electrophysiol; 2018 Nov 01; 41(11):1476-1480. PubMed ID: 30132926
    [Abstract] [Full Text] [Related]

  • 6. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.
    Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G.
    Europace; 2018 Feb 01; 20(2):253-262. PubMed ID: 28520924
    [Abstract] [Full Text] [Related]

  • 7. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S.
    J Am Coll Cardiol; 2013 Sep 03; 62(10):900-8. PubMed ID: 23770182
    [Abstract] [Full Text] [Related]

  • 8. Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial.
    Steffel J, Ruff CT, Braunwald E, Hamershock RA, Murphy SA, Nieminen M, Lanz HJ, Mercuri MF, Peterson N, Antman EM, Giugliano RP.
    Europace; 2019 Feb 01; 21(2):306-312. PubMed ID: 30462220
    [Abstract] [Full Text] [Related]

  • 9. Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
    Kosiuk J, Koutalas E, Doering M, Sommer P, Rolf S, Breithardt OA, Nedios S, Dinov B, Hindricks G, Richter S, Bollmann A.
    Europace; 2014 Jul 01; 16(7):1028-32. PubMed ID: 24489073
    [Abstract] [Full Text] [Related]

  • 10. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation.
    Stam-Slob MC, Connolly SJ, van der Graaf Y, van der Leeuw J, Dorresteijn JAN, Eikelboom JW, Peters RJG, Alings M, Visseren FLJ.
    Circulation; 2019 Jun 18; 139(25):2846-2856. PubMed ID: 31046423
    [Abstract] [Full Text] [Related]

  • 11. Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study.
    Calkins H, Willems S, Verma A, Schilling R, Hohnloser SH, Okumura K, Nordaby M, Kleine E, Bis B, Gerstenfeld EP.
    Europace; 2019 Jun 01; 21(6):879-885. PubMed ID: 30982849
    [Abstract] [Full Text] [Related]

  • 12. Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case-control study.
    Kosiuk J, Koutalas E, Doering M, Nedios S, Sommer P, Rolf S, Darma A, Breithardt OA, Dinov B, Hindricks G, Richter S, Bollmann A.
    Circ J; 2014 Jun 01; 78(10):2402-7. PubMed ID: 25253506
    [Abstract] [Full Text] [Related]

  • 13. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
    Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer MA, Grimaldi M, RE-CIRCUIT Investigators.
    N Engl J Med; 2017 Apr 27; 376(17):1627-1636. PubMed ID: 28317415
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI, Peacock WF, Bunz TJ, Alberts MJ.
    Stroke; 2017 Aug 27; 48(8):2142-2149. PubMed ID: 28655814
    [Abstract] [Full Text] [Related]

  • 15. Pacemaker or defibrillator surgery without interruption of anticoagulation.
    Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS, Ayala-Paredes F, Coutu B, Leiria TL, Essebag V, BRUISE CONTROL Investigators.
    N Engl J Med; 2013 May 30; 368(22):2084-93. PubMed ID: 23659733
    [Abstract] [Full Text] [Related]

  • 16. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.
    Cheung CL, Sing CW, Lau WCY, Li GHY, Lip GYH, Tan KCB, Cheung BMY, Chan EWY, Wong ICK.
    Cardiovasc Diabetol; 2021 Mar 25; 20(1):71. PubMed ID: 33766030
    [Abstract] [Full Text] [Related]

  • 17. Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran.
    Kolb JM, Flack KF, Chatterjee-Murphy P, Desai J, Wallentin LC, Ezekowitz M, Connolly S, Reilly P, Brueckmann M, Ilgenfritz J, Aisenberg J.
    Dig Dis Sci; 2018 Jul 25; 63(7):1878-1889. PubMed ID: 29582237
    [Abstract] [Full Text] [Related]

  • 18. Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies.
    Proietti R, Porto I, Levi M, Leo A, Russo V, Kalfon E, Biondi-Zoccai G, Roux JF, Birnie DH, Essebag V.
    Eur Rev Med Pharmacol Sci; 2015 Apr 25; 19(8):1461-79. PubMed ID: 25967723
    [Abstract] [Full Text] [Related]

  • 19. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial.
    Reinhardt SW, Desai NR, Tang Y, Jones PG, Ader J, Spertus JA.
    PLoS One; 2021 Apr 25; 16(8):e0256338. PubMed ID: 34411158
    [Abstract] [Full Text] [Related]

  • 20. Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation.
    Huybrechts KF, Gopalakrishnan C, Bartels DB, Zint K, Gurusamy VK, Landon J, Schneeweiss S.
    Clin Pharmacol Ther; 2020 Jun 25; 107(6):1405-1419. PubMed ID: 31869437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.